Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CSL ( (AU:CSL) ) just unveiled an update.
CSL Limited has announced an update regarding its ongoing on-market buy-back program for its ordinary fully paid securities. As of the latest notification, the company has bought back a total of 1,807,326 securities before the previous day and an additional 39,141 securities on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$225.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company that specializes in the development and delivery of innovative biotherapies and influenza vaccines. The company is a leader in the biotechnology industry, focusing on the production of life-saving medicines and vaccines that address serious medical conditions.
YTD Price Performance: -35.16%
Average Trading Volume: 1,361,230
Technical Sentiment Signal: Sell
Current Market Cap: A$86.86B
Learn more about CSL stock on TipRanks’ Stock Analysis page.